CJC-1295 vs Ipamorelin

What is the difference between CJC-1295 and ipamorelin?

CJC-1295 is a GHRH analog that tells the pituitary to make more growth hormone, while ipamorelin is a selective GH secretagogue that triggers a separate ghrelin-type receptor to release stored GH.

Both compounds end up raising growth hormone, but they push on different levers. Growth hormone from the pituitary is governed by at least two upstream signals: growth hormone releasing hormone (GHRH), which drives production, and ghrelin acting on the GH secretagogue receptor (GHS-R), which prompts release. CJC-1295 was designed to imitate GHRH. Ipamorelin was designed to imitate the ghrelin signal in a clean, targeted way.

Because they target two receptors, researchers describe their signals as complementary. That is the core reason you see them named together in the same research conversation rather than framed as rivals.

How does CJC-1295 work?

CJC-1295 is a modified GHRH analog that raised growth hormone roughly 2 to 10 fold and sustained GH and IGF-1 elevations for an extended period after dosing (Teichman et al., 2006).

The original design goal was longer action. Native GHRH breaks down in minutes. CJC-1295 was engineered to resist that breakdown, which is why a single administration produced measurable GH and IGF-1 increases lasting days rather than minutes in the reported study (Teichman et al., 2006). It works upstream, at the GHRH receptor, encouraging the pituitary to synthesize and release more GH in a pattern that still depends on the body's own regulation.

How does ipamorelin work?

Ipamorelin is a selective GH secretagogue that releases growth hormone through the ghrelin (GHS) receptor while showing minimal effect on cortisol and prolactin in the original study (Raun et al., 1998).

Selectivity was the notable finding. Earlier secretagogues could raise stress-linked hormones such as cortisol and prolactin alongside GH. Ipamorelin was reported to release GH without those off-target rises, which is why it is often described as a "clean" or selective secretagogue (Raun et al., 1998). It acts downstream of CJC-1295, at a different receptor, prompting the release of GH that the pituitary already holds.

Why are CJC-1295 and ipamorelin studied together instead of against each other?

They are studied together because they act on two separate receptors, so their GH-releasing signals can add together rather than block one another.

A GHRH analog and a GHS-receptor agonist are not competing for the same target. One encourages GH production and the other prompts GH release. In pharmacology terms, pairing a GHRH-pathway agent with a ghrelin-pathway agent is a way to engage both arms of GH control at once. That is the framing you will find in the combined research literature, and it is why "CJC-1295 vs ipamorelin" is less a contest than a description of two parts of one system. For the combined view, see our full CJC-1295 and ipamorelin guide.

CJC-1295 vs ipamorelin: decision table

The table below summarizes what published research reports about each compound. It is not a dosing recommendation.

What are the reported side-effect and safety differences?

The clearest reported safety distinction is ipamorelin's selectivity: it raised GH with minimal cortisol and prolactin effect, while CJC-1295's profile centers on its long duration of GH and IGF-1 elevation (Raun et al., 1998; Teichman et al., 2006).

Long-term human safety data for either compound is limited. Both act on the GH axis, and sustained elevation of GH or IGF-1 is a general area of clinical caution because of downstream effects on insulin sensitivity and glucose handling seen with other GH-axis agents. For comparison within the same class, the oral secretagogue MK-677 was reported to raise fasting glucose and lower insulin sensitivity in older adults (Nass et al., 2008), which illustrates why GH-axis compounds warrant clinician oversight. Neither CJC-1295 nor ipamorelin has the kind of large, long-duration outcome trials that would settle these questions. Any individual assessment belongs with a qualified clinician.

Which one is "better"?

Neither is categorically better; they answer different pharmacology questions, and the research describes them as complementary rather than interchangeable.

If a study is asking "can we drive more GH production over a longer window," CJC-1295's long-acting GHRH-analog profile is the relevant tool (Teichman et al., 2006). If the question is "can we prompt a clean GH pulse without raising cortisol or prolactin," ipamorelin's selectivity is the relevant finding (Raun et al., 1998). The "vs" framing common in searches does not match how the literature treats them.